Barr (A.G.) Regulatory News (BAG)

IMMEDIATE RELEASE 28 August 2025

A.G. BARR p.l.c.

("A.G. BARR" or "the Company")

2025 Annual General Meeting Update

A.G. BARR, the multi-beverage business with a portfolio of market-leading UK brands including IRN-BRU, Rubicon, Boost and FUNKIN, today provides an update regarding the actions taken following the outcome of Resolution 4 at the 2025 Annual General Meeting ("AGM"), held on 23 May 2025, in line with Provision 4 of the UK Corporate Governance Code.

As previously announced, Resolution 4 was supported by a clear majority of our shareholders, with 79.5% in support. However, the Board acknowledges that a minority of shareholders voted against.

Following the AGM, the Company undertook a consultation process with those shareholders. The feedback received indicated that the overall composition of the Board remained an area for enhancement, with a particular focus on improving diversity. As Chair of the Nomination Committee, accountability for this was attributed to the Chair of the Board.

The Company values and prioritises Board diversity in all of its forms and is committed to fostering a Board that encompasses a broad range of perspectives, experiences, and backgrounds. The Board ensures all appointments are made through a rigorous process, focusing on selecting the most suitable candidates to support the long-term success of the business.

Board composition and the potential addition of another Independent Non-Executive Director was a strong consideration for the Board during 2024, and a formal recruitment process took place in early 2025. This process resulted in the appointment of Dr Rohit Dhawan, as announced on 29 July 2025. Rohit brings significant experience in transforming businesses through data, AI and digital innovation, bringing a complementary skill set and adding to the breadth of perspectives on the Board.

The Board would like to thank shareholders for their constructive engagement and feedback, and will continue to consult with shareholders, as appropriate, in respect of the Company's ongoing nomination practices. 

For more information, please contact: